ViaCyte to Participate in 2022 Advanced Technologies & Treatments for Diabetes Conference

Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

ViaCyte to Participate in 2022 Advanced Technologies & Treatments for Diabetes Conference

PR Newswire

Dr. Manasi Jaiman, newly appointed Chief Medical Officer, to discuss patient-reported outcomes associated with cell therapy in type 1 diabetes

SAN DIEGO, April 20, 2022 /PRNewswire/ -- Manasi Sinha Jaiman, M.D., M.P.H., who was recently appointed Chief Medical Officer at ViaCyte, Inc., a clinical-stage cellular therapy company with an advanced stem cell platform that delivers therapeutic proteins to restore health in people with endocrine disorders, will participate in the 15th International Conference on Advanced Technologies & Treatments for Diabetes' (ATTD) session, Utility of PROs in Therapy Development for Type 1 Diabetes: Putting the End-User Upfront.

Dr. Jaiman will discuss patient-reported outcomes (PROs) associated with cell therapy in type 1 diabetes (T1D) on Thursday, April 28, 2022, from 17:20 - 17:35 CEST. The session is organized by JDRF, the leading global funder of T1D research.

"Multiple factors drive patients' interest in participating in cell therapy clinical trials, and their personal experiences may not always be represented by traditional clinical indicators, including A1C," said Dr. Jaiman. "Given the diversity of perspectives and the lack of PRO questionnaires specific to diabetes cell therapy, we need to be looking at additional research to capture clinically meaningful patient-reported outcomes."

Prior to being named Chief Medical Officer, Dr. Jaiman served as Vice President, Clinical Development at ViaCyte. She is focused on leading the development of stem cell therapy programs within the diabetes space toward the goal of changing the paradigm of medical care for patients with T1D. Dr. Jaiman is a pediatric endocrinologist with extensive experience in T1D research from the industry and academia, including working on the bionic pancreas trials at Massachusetts General Hospital and T1  and T2 diabetes drug and device development at Covance. Her experience with patients  informs not only her drive to find a cure but also her understanding of what it would mean to patients and families.

About ViaCyte
ViaCyte is a clinical-stage cellular therapy company with an advanced stem cell platform that delivers therapeutic proteins to restore health in people with endocrine disorders. The platform includes a rigorously tested, regulatory-compliant proprietary cell line, gene-editing technology designed to eliminate the need for immunosuppression, and delivery systems consisting of simple, durable and retrievable devices placed under the skin. ViaCyte is currently evaluating its stem cell product candidates as a potential long-term treatment for patients with type 1 diabetes. The company was the first to bring into the clinic a gene-edited, immune-evasive cell therapy to treat patients with type 1 diabetes. To accelerate and expand the company's research capabilities, ViaCyte has established collaborative partnerships with leading companies, including CRISPR Therapeutics and W.L. Gore & Associates. ViaCyte is headquartered in San Diego, California. For more information, please visit www.viacyte.com and connect with ViaCyte on TwitterFacebook, and LinkedIn.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/viacyte-to-participate-in-2022-advanced-technologies--treatments-for-diabetes-conference-301528796.html

SOURCE ViaCyte, Inc.

Copyright CNW Group 2022

Comment On!

140
Upload limit is up to 1mb only
To post messages to your Socail Media account, you must first give authorization from the websites. Select the platform you wish to connect your account to CanadianInsider.com (via Easy Blurb).